Last reviewed · How we verify
QLS4131 Injection
At a glance
| Generic name | QLS4131 Injection |
|---|---|
| Also known as | A novel tri-specific humanized antibody |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus (PHASE1)
- A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS4131 Injection CI brief — competitive landscape report
- QLS4131 Injection updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI